Avid Bioservices (NASDAQ: IFRX) and Inflarx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

21.7% of Avid Bioservices shares are owned by institutional investors. Comparatively, 54.8% of Inflarx shares are owned by institutional investors. 0.9% of Avid Bioservices shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Avid Bioservices and Inflarx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avid Bioservices -40.68% -58.67% -31.70%
Inflarx N/A N/A N/A

Valuation and Earnings

This table compares Avid Bioservices and Inflarx’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avid Bioservices $53.62 million 6.34 -$21.81 million ($0.50) -12.14
Inflarx N/A N/A -$27.39 million ($2.94) -11.17

Avid Bioservices has higher revenue and earnings than Inflarx. Avid Bioservices is trading at a lower price-to-earnings ratio than Inflarx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Avid Bioservices and Inflarx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avid Bioservices 0 0 5 0 3.00
Inflarx 0 0 6 0 3.00

Avid Bioservices presently has a consensus price target of $7.50, suggesting a potential upside of 23.56%. Inflarx has a consensus price target of $42.67, suggesting a potential upside of 29.92%. Given Inflarx’s higher possible upside, analysts plainly believe Inflarx is more favorable than Avid Bioservices.

Summary

Inflarx beats Avid Bioservices on 7 of the 11 factors compared between the two stocks.

Avid Bioservices Company Profile

Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.